Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: A 12-month, randomized, double-blind, placebo-controlled clinical trial

Clinical Therapeutics

Volumn 26, Issue 9, 2004, Pages 1427-1435

  Sanchez Reyes, Leticia ^a   Fanghanel, Guillermo ^a,c   Yamamoto, Jorge ^a   Martinez Rivas, Lourdes ^a   Campos Franco, Enrique ^a   Berber, Arturo ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b ABBOTT LABORATORIES   (United States)

^c Coyoacan CP 04320 Mex City DF M ^*

Author keywords

diabetes mellitus; obesity; overweight; placebo controlled trial; sibutramine

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; PLACEBO; SIBUTRAMINE;

ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION;

ADULT; AGED; APPETITE DEPRESSANTS; BLOOD GLUCOSE; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OBESITY; TIME FACTORS; WEIGHT LOSS;

EID: 9644288282     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.09.017     Document Type: Article

References (31)

1. Anderson P.J., Critchley J.A., and Chan J.C. Factor analysis of the metabolic syndrome: Obesity vs insulin resistance as the central abnormality Int J Obes Relat Metab Disord 25 2001 1782 1788
2. Meigs J.B., D'Agostino R.B., and Wilson P.W. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study Diabetes 46 1997 1594 1600
3. Serrano Rios M. Epidemiology of cardiovascular disease in type 2 diabetes Int J Clin Pract Suppl 121 2001 4 7
4. Williams G. Obesity and type 2 diabetes: A conflict of interests? Int J Obes Relat Metab Disord 23 Suppl 7 1999 S2 S4
5. Grundy S.M., Garber A., and Goldberg R. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: Lifestyle and medical management of risk factors Circulation 105 2002 E153 E158
6. Grundy S.M., Benjamin I.J., and Burke G.L. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association Circulation 100 1999 1134 1146
7. Campbell L., and Rossner S. Management of obesity in patients with type 2 diabetes Diabet Med 18 2001 345 354
8. Tremble J.M., and Donaldson D. Is continued weight gain inevitable in type 2 diabetes mellitus? J R Soc Health 119 1999 235 239
9. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA 281 1999 2005 2012
10. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
11. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Arch Intern Med 158 1998 1855 1867
12. McNeely W., and Goa K.L. Sibutramine: A review of its contribution to the management of obesity Drugs 56 1998 1093 1124
13. Stock M.J. Sibutramine: A review of the pharmacology of a novel anti-obesity agent Int J Obes Relat Metab Disord 21 Suppl 1 1997 S25 S29
14. Finer N., Bloom S.R., and Frost G.S. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study Diabetes Obes Metab 2 2000 105 112
15. Fujioka K., Seaton T.B., and Rowe E. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus Diabetes Obes Metab 2 2000 175 187
16. Serrano-Rios M., Melchionda N., and Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy Diabet Med 19 2002 119 124
17. Gokcel A., Karakose H., and Ertorer E.M. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control Diabetes Care 24 2001 1957 1960
18. McNulty S.J., Ur E., Williams G. Multicenter Sibutramine Study Group A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin Diabetes Care 26 2003 125 131
19. Haffner S.M., Hazuda H.P., and Mitchell B.D. Increased incidence of type II diabetes mellitus in Mexican Americans Diabetes Care 14 1991 102 108
20. Valdez R., Gonzalez-Villalpando C., and Mitchell B.D. Differential impact of obesity in related populations Obes Res 3 Suppl 2 1995 S223 S232
21. Haffner S.M. Epidemiology of type 2 diabetes: Risk factors Diabetes Care 21 Suppl 3 1998 C3 C6
22. Stern M.P., and Haffner S.M. Type II diabetes and its complications in Mexican Americans Diabetes Metab Rev 6 1990 29 45
23. Haffner S.M., Mitchell B.D., Stern M.P., and Hazuda H.P. Macrovascular complications in Mexican Americans with type II diabetes Diabetes Care 14 1991 665 671
24. (Suppl) Kotler D.P., Burastero S., Wang J., and Pierson R.N. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease Am J Clin Nutr 64 1996 5489 5497
25. Fanghanel G., Cortinas L., Sanchez-Reyes L., and Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity Int J Obes Relat Metab Disord 24 2000 144 150
26. Smith I.G., Goulder M.A., and Sibutramine Clinical Study 1047 Team Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity J Fam Pract 50 2001 505 512
27. James W.P., Astrup A., Finer N. STORM Study Group Effect of sibutramine on weight maintenance after weight loss: A randomised trial Lancet 356 2000 2119 2125
28. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
29. Stratton I.M., Adler A.I., and Neil H.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 321 2000 405 412
30. Lemieux S., Prud'homme D., and Tremblay A. Anthropometric correlates to changes in visceral adipose tissue over 7 years in women Int J Obes Relat Metab Disord 20 1996 618 624
31. Han T.S., van Leer E.M., Seidell J.C., and Lean M.E. Waist circumference action levels in the identification of cardiovascular risk factors: Prevalence study in a random sample BMJ 311 1995 1401 1405